Skip to main content

28.10.2024 | original report

BACE (Bendamustine, Cytarabine, Cyclophosphamide and Etoposide) conditioning regime for patients with lymphoma undergoing autologous stem cell transplant

verfasst von: Dr. Joydeep Chakrabartty, Dr. Arijit Bishnu, Dr. Akash Bhojgaria, Sara Panmei, Mihir Das, Keisam Sanjita Devi

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten

Summary

Autologous stem cell transplant (ASCT) is a curative treatment for lymphomas. BEAM conditioning (Carmustine, Etoposide, Cytarabine, Melphalan) is widely used but can cause severe side effects. This study investigated the effectiveness and safety of a BACE regimen (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) as an alternative to BEAM in patients with relapsed/refractory lymphomas. The study included 28 patients who received BACE followed by ASCT. The results showed good tolerability with minimal grade III-IV mucositis, no pulmonary or renal toxicity, and a low transplant-related mortality rate (0% at day 30). The overall survival rate at 2 years was 77%, and the relapse-free survival rate was 85%. Compared to other BCNU-alternative regimens, BACE demonstrated favorable outcomes with a lower relapse rate (14.3%). Engraftment times were also faster compared to BCNU-containing regimens. Limitations include the single-center design and the potential selection bias due to pre-transplant response. Further research with larger patient groups is needed to confirm these findings. This study suggests that BACE could be a promising alternative to BEAM for ASCT in relapsed/ refractory lymphomas, offering similar effectiveness with potentially reduced side effects.
Literatur
1.
Zurück zum Zitat Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184.CrossRefPubMedPubMedCentral Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.CrossRefPubMed Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.CrossRefPubMed
3.
Zurück zum Zitat Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, et al. High-dose therapy followed by stem cell transplantation in Hodgkin’s lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451–64.CrossRefPubMed Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, et al. High-dose therapy followed by stem cell transplantation in Hodgkin’s lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451–64.CrossRefPubMed
4.
Zurück zum Zitat Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol. 1986;16:170–5.CrossRefPubMed Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol. 1986;16:170–5.CrossRefPubMed
5.
Zurück zum Zitat Till BG, Madtes DK. BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma. 2012;53(6):1019–20.CrossRefPubMed Till BG, Madtes DK. BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma. 2012;53(6):1019–20.CrossRefPubMed
6.
Zurück zum Zitat Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant. 2018;24(9):1814–22.CrossRefPubMed Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant. 2018;24(9):1814–22.CrossRefPubMed
7.
Zurück zum Zitat Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653–5.CrossRefPubMed Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653–5.CrossRefPubMed
8.
Zurück zum Zitat Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309–17.CrossRefPubMed Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309–17.CrossRefPubMed
9.
Zurück zum Zitat Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204–10.CrossRefPubMed Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204–10.CrossRefPubMed
10.
Zurück zum Zitat Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncologist. 2013;18(8):954–64.CrossRefPubMedPubMedCentral Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncologist. 2013;18(8):954–64.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244.CrossRefPubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244.CrossRefPubMed
12.
Zurück zum Zitat Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B‑cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 2011;29(2):75–80.CrossRefPubMed Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B‑cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 2011;29(2):75–80.CrossRefPubMed
13.
Zurück zum Zitat Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95.CrossRefPubMed Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95.CrossRefPubMed
14.
Zurück zum Zitat Stahl W, Eisenbrand G. Comparative study on the influence of two 2‑chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione related enzymes in different organs of the rat. Free Radic Res Commun. 1991;14(4):271–8.CrossRefPubMed Stahl W, Eisenbrand G. Comparative study on the influence of two 2‑chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione related enzymes in different organs of the rat. Free Radic Res Commun. 1991;14(4):271–8.CrossRefPubMed
15.
Zurück zum Zitat AlJohani NI, Nasani M, Ahmed HE, Rehman JU, Nawaz A, Alzahrani Z, Albeirouti B. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Stem Cell Ther. 2021;14(4):327–35.CrossRef AlJohani NI, Nasani M, Ahmed HE, Rehman JU, Nawaz A, Alzahrani Z, Albeirouti B. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Stem Cell Ther. 2021;14(4):327–35.CrossRef
16.
Zurück zum Zitat Dikshit N, Sinha R, Maity H, et al. Dose escalation study of bendamustine based conditioning regime (Bace-bendamustine, cytarabine,cyclophosphamide and etoposide) in patients with lymphoma undergoing autologous stem cell transplant. Hematol Transfus Int J. 2017;5(5):294–7. Dikshit N, Sinha R, Maity H, et al. Dose escalation study of bendamustine based conditioning regime (Bace-bendamustine, cytarabine,cyclophosphamide and etoposide) in patients with lymphoma undergoing autologous stem cell transplant. Hematol Transfus Int J. 2017;5(5):294–7.
17.
Zurück zum Zitat Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, et al. Bendamustine-based conditioning for non- 447 Hodgkin lymphoma autologous transplantation: an increasing 448 risk of renal toxicity. Bone Marrow Transplant. 2016;51:319–21.CrossRefPubMed Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, et al. Bendamustine-based conditioning for non- 447 Hodgkin lymphoma autologous transplantation: an increasing 448 risk of renal toxicity. Bone Marrow Transplant. 2016;51:319–21.CrossRefPubMed
18.
Zurück zum Zitat Gupta A, Gokarn, Anant, Rajamanickam, Deepan, Punatar S, Thippeswamy R, Libin M, Bagal, Bhausaheb, Kannan, Sadhana, Khattry N. Lomustine, cytarabine, cyclophosphamide, etoposide—An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. J Can Res Ther. 2018;14(5):926–33. https://doi.org/10.4103/0973-1482.181183.CrossRef Gupta A, Gokarn, Anant, Rajamanickam, Deepan, Punatar S, Thippeswamy R, Libin M, Bagal, Bhausaheb, Kannan, Sadhana, Khattry N. Lomustine, cytarabine, cyclophosphamide, etoposide—An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. J Can Res Ther. 2018;14(5):926–33. https://​doi.​org/​10.​4103/​0973-1482.​181183.CrossRef
Metadaten
Titel
BACE (Bendamustine, Cytarabine, Cyclophosphamide and Etoposide) conditioning regime for patients with lymphoma undergoing autologous stem cell transplant
verfasst von
Dr. Joydeep Chakrabartty
Dr. Arijit Bishnu
Dr. Akash Bhojgaria
Sara Panmei
Mihir Das
Keisam Sanjita Devi
Publikationsdatum
28.10.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00994-6